Compare ERC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | TLSI |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | 110 |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.5M | 267.1M |
| IPO Year | N/A | N/A |
| Metric | ERC | TLSI |
|---|---|---|
| Price | $9.01 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 79.2K | ★ 200.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $41.93 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | $12.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.65 | $3.42 |
| 52 Week High | $9.78 | $7.95 |
| Indicator | ERC | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 20.91 | 33.86 |
| Support Level | N/A | $3.61 |
| Resistance Level | $9.45 | $5.51 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 8.51 | 3.90 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.